Company intelligence / Profile preview

Microviable Therapeutics

Gijón/Xixón, Asturias, Spainmicroviable.com ↗
Ownership
Private
Development stage
Preclinical
01

Overview

Microviable Therapeutics develops next-generation live biotherapeutic products based on commensal human bacteria. Its lead program, MVT‑201—a cGMP-produced oral capsule representing a complete microbiota ecosystem—has shown positive preclinical results and was planned to enter clinical trials in late 2023. The company leverages its proprietary PharmaBiota® platform and a large strain collection to develop both full-microbiome and rationally designed consortia therapies targeting infectious diseases and other conditions. No published clinical trial results are available yet.

Therapeutic areas
OncologyGastroenterologyInfectious Diseases
Modalities
Live biotherapeutic products (LBPs)Complete microbiota ecosystem productsRationally defined bacterial consortia
Industry
Biotech
02

Drug pipeline

3 assets

MVT-201

Preclinical

2 more assets in the full pipeline.

03

Partnerships

Inmunomet Intolerancias y Disbiosis SL

Beyond the preview

Go deeper on Microviable Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Microviable Therapeutics.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call